| Autor: |
Van Laar, Amber D., Van Laar, Victor S., San Sebastian, Waldy, Merola, Aristide, Elder, J. Bradley, Lonser, Russell R., Bankiewicz, Krystof S., Björklund, Anders, Bloem, Bastiaan R., Brundin, Patrik, Federoff, Howard |
| Předmět: |
|
| Zdroj: |
Journal of Parkinson's Disease; 2021 Supplement 2s, Vol. 11, pS173-S182, 10p |
| Abstrakt: |
At present there is a significant unmet need for clinically available treatments for Parkinson's disease (PD) patients to stably restore balance to dopamine network function, leaving patients with inadequate management of symptoms as the disease progresses. Gene therapy is an attractive approach to impart a durable effect on neuronal function through introduction of genetic material to reestablish dopamine levels and/or functionally recover dopaminergic signaling by improving neuronal health. Ongoing clinical gene therapy trials in PD are focused on enzymatic enhancement of dopamine production and/or the restoration of the nigrostriatal pathway to improve dopaminergic network function. In this review, we discuss data from current gene therapy trials for PD and recent advances in study design and surgical approaches. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
